SILO PHARMA, INC. Net Income (Loss) Attributable to Noncontrolling Interest
SILO PHARMA, INC. (SILO) reported Net Income (Loss) Attributable to Noncontrolling Interest of $1.92 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-11.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2023-08-11
- SILO PHARMA, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2023-06-30 was $1.01M, a 53.85% increase year-over-year.
- SILO PHARMA, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2023-03-31 was $906.40K, a 50.05% increase year-over-year.
- SILO PHARMA, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2022-12-31 was $1.66M, a 30.70% decline year-over-year.
- SILO PHARMA, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2022-09-30 was $983.25K.
- SILO PHARMA, INC. net income (loss) attributable to noncontrolling interest for fiscal 2022 was $3.91M, a 0.12% increase from fiscal 2021.
- SILO PHARMA, INC. net income (loss) attributable to noncontrolling interest for fiscal 2021 was $3.90M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2023-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $1.92M 10-Q · filed 2023-08-11 | $3.58M derived: sum of 3 quarters · filed 2023-08-11 | $4.57M derived: sum of 4 quarters · filed 2023-08-11 |
| 2023-03-31 | $906.40K 10-Q · filed 2023-05-12 | $2.57M derived: sum of 2 quarters · filed 2023-05-12 | $3.55M derived: sum of 3 quarters · filed 2023-05-12 | $4.21M derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $2.65M derived: sum of 2 quarters · filed 2023-03-24 | $3.30M derived: sum of 3 quarters · filed 2023-03-24 | $3.91M 10-K · filed 2023-03-24 |
| 2022-09-30 | $983.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.64M derived: sum of 2 quarters · filed 2022-11-10 | $2.25M 10-Q · filed 2022-11-10 | $4.65M derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | $658.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $1.26M 10-Q · filed 2022-08-01 | $3.66M derived: sum of 3 quarters · filed 2022-08-01 | |
| 2022-03-31 | $604.07K 10-Q · filed 2022-05-13 | $3.00M derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2021-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $3.90M 10-K · filed 2022-03-28 | ||
| 2021-09-30 | $1.50M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |